Skip to main content

Optimized Diagnostics for Improved Treatment Stratification in Invasive Fungal Diseases

Objective

Invasive fungal disease (IFD) is a leading cause of morbidity and mortality in the growing number of immunocompromised individuals, including particularly cancer patients, and bone-marrow or organ transplant recipients. The majority of IFD events are still caused by Candida and Aspergillus species, but there is an increasing incidence of resistant or previously uncommon moulds, yeasts and Zygomycetes. Timely pathogen detection is a prerequisite for effective therapy in patients with IFD.
FUNGITECT will focus on this medical priority and develop, validate and market a specific set of novel molecular diagnostic tests for IFD targeting fungal DNA-, RNA- and protein motifs, as well as the enzymatic activity of fungal pathogens. Additionally, FUNGITECT will provide a unique opportunity to establish and implement highly effective diagnostic assays supported by Next-Generation Sequencing and a bioinformatics service platform, facilitating optimized treatment strategies adapted to individual patient requirements with the following paramount aims: i) to provide the diagnostic basis for stratified and timely administration of the most appropriate antifungal therapy permitting improved management of patients with IFD, ii) to decrease the rate of overtreatment and the ensuing adverse side effects including fungal resistance, and iii) to help reduce the enormous healthcare costs for clinical antifungal therapy. The consortium includes leading academic research institutions, SMEs and Industry already successfully positioned in the market.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /social sciences/sociology/demography/mortality
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

ST. ANNA KINDERKREBSFORSCHUNG
Address
Zimmermannplatz 10
1090 Wien
Austria
Activity type
Research Organisations
EU contribution
€ 1 681 240
Administrative Contact
Nuno Andrade (Dr.)

Participants (5)

MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 1 000 918
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Graham Warren (Prof.)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 980 616,61
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
Administrative Contact
Christoph Schulte (Mr.)
JAVNA USTANOVA UNIVERZITET U TUZLI UNIVERSITAS STUDIORUM TUZLAENSIS
Bosnia and Herzegovina
EU contribution
€ 375 870,40
Address
Dr Tihomila Markovica 1
75000 Tuzla
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Nadira Ibrišimović (Dr.)
GENEDATA AG
Switzerland
EU contribution
€ 968 287,20
Address
Margarethenstrasse 38
4053 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Thomas Hartsch (Dr.)
MOLZYM GMBH & CO KG
Germany
EU contribution
€ 837 485,79
Address
Mary-astell-strasse 10
28359 Bremen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Lorenz (Prof.)